Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Matthew John Weiss

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0553-248X; OpenAlex author ID A5014748431. Sources: ClinicalTrials.gov.

Their work

Papers
79 (first author 1, last author 9)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
273
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 6 papers · 2016: 5 papers · 2017: 8 papers, 1 trial · 2018: 14 papers · 2019: 13 papers · 2020: 6 papers · 2021: 7 papers · 2022: 7 papers · 2023: 4 papers · 2024: 5 papers · 2025: 2 papers

Papers 50 of 79

  1. Trends and Outcomes of Neoadjuvant Chemotherapy for Clinical Stage T1 Pancreatic Cancer. Co-author DOI 10.1002/jso.28003↗
  2. Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol32020103↗
  3. Comparison of neoadjuvant chemotherapy plus radiation vs. chemotherapy alone on complete pathologic response in pancreatic adenocarcinoma: an analysis of the n… Co-author DOI 10.1007/s44337-024-00145-0↗
  4. Factors associated with radiological misstaging of pancreatic ductal adenocarcinoma: A retrospective observational study. Co-author DOI 10.1067/j.cpradiol.2024.03.001↗
  5. Surgery for Oligometastatic Pancreatic Cancer: Defining Biologic Resectability. Last author DOI 10.1245/s10434-024-15129-8↗
  6. Minorities Face Delays to Pancreatic Cancer Treatment Regardless of Diagnosis Setting. Co-author DOI 10.1245/s10434-024-15352-3↗
  7. ASO Author Reflections: Identifying and Understanding How Vulnerable Populations Are Affected by Delays in Pancreatic Cancer Care. Co-author DOI 10.1245/s10434-024-15476-6↗
  8. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. Co-author DOI 10.1002/jhbp.1303↗
  9. Performance of the 7 th and 8 th Editions of the American Joint Committee on Cancer Staging System in Patients with Intraductal Papillary Mucinous Neoplasm-Ass… Co-author DOI 10.1097/sla.0000000000005313↗
  10. Development of a Neoadjuvant Treatment Pathway to Standardize Pancreatic Cancer Care and Improve Outcomes Across a Large Diverse Health System Co-author DOI 10.1101/2023.09.19.23295749↗
  11. Plasma cells in human pancreatic ductal adenocarcinoma secrete antibodies against self-antigens. Co-author DOI 10.1172/jci.insight.172449↗
  12. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients trea… Co-author DOI 10.1002/cam4.4527↗
  13. Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-021-06410-y↗
  14. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled… Co-author DOI 10.1016/j.prro.2022.02.009↗
  15. Geographic variation in attitudes regarding management of locally advanced pancreatic cancer. Co-author DOI 10.1016/j.sopen.2022.07.007↗
  16. Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy. Last author DOI 10.1097/sla.0000000000005558↗
  17. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10663-1↗
  18. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderlin… Co-author DOI 10.1245/s10434-021-11202-8↗
  19. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  20. Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice. Co-author DOI 10.1097/sla.0000000000003568↗
  21. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003570↗
  22. Comment on "Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve". Last author DOI 10.1097/sla.0000000000004789↗
  23. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  24. Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. Co-author DOI 10.1200/cci.21.00001↗
  25. Optimizing Patient Selection for Irreversible Electroporation of Locally Advanced Pancreatic Cancer: Analyses of Survival. Co-author DOI 10.3389/fonc.2021.817220↗
  26. Increasing access to multidisciplinary care in pancreatic cancer. Last author DOI 10.1002/pon.5493↗
  27. Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04230-z↗
  28. Disparities in the Use of Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-019-04311-z↗
  29. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Co-author DOI 10.1007/s13304-020-00710-z↗
  30. Evaluation of a Novel Absorbable Radiopaque Hydrogel in Patients Undergoing Image Guided Radiation Therapy for Borderline Resectable and Locally Advanced Pancr… Co-author DOI 10.1016/j.prro.2020.01.013↗
  31. Radical antegrade modular pancreatosplenectomy versus standard distal pancreatosplenectomy for pancreatic cancer, a dual-institutional analysis. Co-author DOI 10.21037/cco-20-6↗
  32. Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. Co-author DOI 10.1002/path.5194↗
  33. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. Co-author DOI 10.1007/s11605-018-3966-8↗
  34. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.04.007↗
  35. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. Co-author DOI 10.1016/j.hpb.2018.12.002↗
  36. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from … Co-author DOI 10.1016/j.hpb.2018.12.004↗
  37. Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. Co-author DOI 10.1038/s41379-018-0183-7↗
  38. Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. Co-author DOI 10.1038/s41379-019-0317-6↗
  39. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  40. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002734↗
  41. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Co-author DOI 10.1097/sla.0000000000002753↗
  42. Pancreatic cancer cells assemble a CXCL12-keratin 19 coating to resist immunotherapy Co-author DOI 10.1101/776419↗
  43. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-0197↗
  44. Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-07261-7↗
  45. Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.25288↗
  46. Pancreaticoduodenectomy and Superior Mesenteric Vein Resection Without Reconstruction for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-018-3684-2↗
  47. Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation thera… Co-author DOI 10.1016/j.adro.2018.07.002↗
  48. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jamcollsurg.2017.12.021↗
  49. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conven… Co-author DOI 10.1016/j.surg.2017.11.027↗
  50. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Co-author DOI 10.1053/j.gastro.2018.05.035↗

Trials 1

  1. Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections Principal investigator NCT03021668↗

Closest collaborators

The 25 strongest of 273 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christopher Lee Wolfgang · 53 shared papers, 2013–2024 · strength 4.30
  2. Jin Peng He · 49 shared papers, 2015–2024 · strength 4.19
  3. Joseph M. Herman · 24 shared papers, 2015–2024 · strength 2.26
  4. Ralph H. Hruban · 27 shared papers, 2015–2023 · strength 2.04
  5. Richard Andrew Burkhart · 19 shared papers, 2018–2023 · strength 1.76
  6. Ammar A. Javed · 18 shared papers, 2017–2024 · strength 1.70
  7. Alex B. Blair · 18 shared papers, 2017–2022 · strength 1.57
  8. Lei Zheng · 19 shared papers, 2015–2022 · strength 1.55
  9. Vincent P. Groot · 17 shared papers, 2018–2022 · strength 1.48
  10. Daniel A. Laheru · 18 shared papers, 2015–2022 · strength 1.36
  11. Oliver J. Standring · 7 shared papers, 2022–2025 · strength 1.34
  12. Ding Ding · 14 shared papers, 2018–2023 · strength 1.30
  13. Georgios Gemenetzis · 15 shared papers, 2018–2022 · strength 1.30
  14. Amol Kumar Narang · 14 shared papers, 2017–2022 · strength 1.27
  15. Gary Deutsch · 6 shared papers, 2022–2025 · strength 1.27
  16. Elliot K. Fishman · 15 shared papers, 2015–2024 · strength 1.25
  17. Jun Yu · 15 shared papers, 2017–2023 · strength 1.21
  18. Danielle K. DePeralta · 6 shared papers, 2022–2025 · strength 1.19
  19. Lyudmyla Demyan · 6 shared papers, 2022–2024 · strength 1.16
  20. Daniel A. King · 6 shared papers, 2022–2025 · strength 1.02
  21. Amy Hacker‐Prietz · 11 shared papers, 2015–2022 · strength 0.87
  22. Michael J. Wright · 7 shared papers, 2019–2024 · strength 0.84
  23. Dung Thi Le · 10 shared papers, 2015–2022 · strength 0.83
  24. Michael Goggins · 12 shared papers, 2016–2020 · strength 0.81
  25. Martin A. Makary · 9 shared papers, 2017–2021 · strength 0.67

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.